相关实验视频

Updated: Jan 9, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

埃米齐祖马布,XVIII因子模仿双特异性单克隆抗体:对血栓生成和血栓等度的影响

Armando Tripodi^1,2, Marigrazia Clerici¹, Erica Scalambrino¹

¹IRCCS Ca' Granda Ospedale Maggiore Policlinico Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

Research and practice in thrombosis and haemostasis

|December 1, 2025

概括

血生成试验 (TGA) 和血栓电平测试可以监测血友病A患者的埃米齐祖马布活性. 在TGA中,血栓峰值和内源性血栓潜力 (ETP),以及在无触发器的血栓凝结仪中凝结时间,与埃米齐祖马布水平有很强的相关性.

科学领域:

血液学血液学血液学
临床化学临床化学
药理学药理学是指药理学的学科.

背景情况:

艾米齐祖马布预防血友病A需要偶尔监测活动.
标准实验室测试艾米齐祖马布的活性是有限的.
全球凝血测试,如TGA和血小板造影,是潜在的工具.

研究的目的:

为了调查TGA和血小板结晶测试结果的变化,埃米齐祖马布治疗的患者.
为了确定最佳的测试条件来评估埃米齐祖马布的活性.
为了将TGA和血栓凝聚度参数与埃米齐祖马布度相关联.

主要方法:

一项体外研究确定了TGA试剂的最佳成分,以确定埃米齐祖马布的剂量反应.
一项ex vivo研究评估了TGA/血栓等度参数与患者的埃米齐祖马布水平之间的相关性.
用不同的组织因子和脂度进行了测试.

主要成果:

TGA血峰值和内源性血潜力 (ETP) 表明对埃米齐祖马布的剂量反应良好.
最佳的TGA条件涉及1 pM组织因子和1 μM脂.
在血栓峰值/ETP和埃米齐祖马布度之间观察到强烈的相关性.
在没有外源触发器的情况下进行的血栓凝聚率计凝固时间与埃米齐祖马布有显著的相关性.

结论:

在较低的组织因子/脂度下,TGA血激素峰值或ETP可以评估埃米齐祖马布的活性.
血栓凝聚率计凝血时间是监测埃米齐祖马布的宝贵工具,当它在没有外源触发器的情况下进行时.

关键词:

血友病 (hemophilia) 是一种病.发生出血发生出血实验室测试实验室测试实验室测试监控监控监控监控监控监控粘性弹性电磁测量 (VES) 是一种粘性弹性电磁测量.

更多相关视频

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

相关概念视频

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...